May 30,2007
Sen. Grassley seeks additional information about pricing and marketing of anti-anemia drugs
WASHINGTON --- Sen. Chuck Grassley is asking a leading drug maker to cooperate with his ongoing inquiry into the pricing and marketing of anti-anemia drugs given to kidney and cancer patients and the Food and Drug Administration’s access to data from the drug maker’s studies of such drugs.
The text of the letter Grassley sent today to Johnson & Johnson is below, along with the text of inquiries he made earlier this month and in April of the Food and Drug Administration, Amgen Inc. and the Centers for Medicare and Medicaid Services.
Grassley is Ranking Member of the Senate Committee on Finance.
###
Next Article Previous Article
Recent News
- Wyden Blasts Trump Weaponization of IRS Against Progressive Speech
- Wyden, Warren, Sanders, Warnock Probe Medicaid Contractors on Faulty Eligibility and Enrollment Systems
- Trumpcare is Already Wreaking Havoc on American Health Care
- Wyden, Finance Democrats Urge Crapo to Investigate Kennedy on Anti-Vax Actions and Conflicts of Interests
- Wyden, Paul, Schumer, and Kaine Introduce Bipartisan Legislation to Repeal Global Tariffs and Restore Congressional Authority Over Trade